For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Vyndamax and Tafamidis meglumine represents a significant advancement . These innovative therapies stabilize the transthyretin protein, preventing its harmful build-up and lessening the impact of the disease . People are now seeing bene